Q-omics provides the consensus-scored DGLUCY profile across patient tissues and cancer cell-line models. DGLUCY expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DGLUCY is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, DGLUCY RNA expression shows 20,282 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where DGLUCY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DGLUCY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DGLUCY survival associations across molecular data types. DGLUCY RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DGLUCY RNA expression–survival associations across cancer types. High DGLUCY expression shows unfavorable associations in UVM, but favorable associations in KIRP, SKCM, CESC, MESO and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DGLUCY RNA expression.
This table summarizes DGLUCY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DGLUCY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DGLUCY shows lower tumor expression in KIRC, THCA, LUAD, COAD, HNSC and BLCA. The KIRC box plot shows higher DGLUCY RNA expression in normal versus tumor tissue (log2 FC = −0.799, t-test p < 0.001).
This table shows molecular features associated with DGLUCY in patient tissues and cancer cell lines. In patient samples, DGLUCY shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DGLUCY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
